Dye-sensitized solar cells (DSSCs) are the third generation of photovoltaic cells developed by Grätzel and O'Regan. They have the characteristics of low cost, simple manufacturing process, tunable optical properties, and higher photoelectric conversion efficiency (PCE). With an ever increasing energy crisis, there is an urgent need to develop highly efficient, environmentally benign, and energy-saving cell materials. Polyoxometalates (POMs), a kind of molecular inorganic quasi-semiconductor, are promising candidates for use in different parts of DSSCs due to their excellent photosensitivity, redox, and catalytic properties, as well as their relative stability. Following a brief introduction to the development of DSSCs and the potential virtues of POMs in DSSCs, we attempt to make some generalizations about the energy level regulation of POMs that is the underlying theoretical basis for their application in DSSCs, and then we summarize the research progress of POMs in DSSCs in recent years. This is organized in terms of the properties of POMs, namely, electron acceptor, photosensitivity, redox and catalysis, based on the accumulation of our research into POMs over many years. Meanwhile, in view of the fact that the properties of POMs depend primarily on their electronic structural diversity, we keep this point in mind throughout the article with a view to revealing their structure-property relationships. Finally we provide a short summary and remarks on the future outlook. This review may be of interest to synthetic chemists devoted to designing POMs with specific structures, and researchers engaged in the extension of POMs to photoelectric materials.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/c8cs00559a | DOI Listing |
This opinion piece explores the opportunities and challenges from increased utilisation of pharmacists and pharmacy technicians in delivery of the UK immunisation programme, within the recent legislative change enabling pharmacy technicians to administer Prescription Only Medicines (POMs) under Patient Group Directions (PGDs).
View Article and Find Full Text PDFInt J Nanomedicine
January 2025
College of Pharmacy, Al-Ain University, Abu Dhabi Campus, Abudhabi, United Arab Emirates.
Purpose: The solid lipid nanoparticles of transitional metal complexes (POMs) were prepared with natural lipids with the aim of developing a safer therapeutic approach for cancer treatment.
Methods: Natural lipids were used to create solid lipid nanoparticles containing transitional metal complexes (POMs).
Results: The nanoparticles had displayed appreciable entrapment and loading percentage of PW.
J Cancer Surviv
January 2025
Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
Purpose: Radiotherapy (RT) for oropharyngeal cancer (OPC) can lead to late toxicity. Fatigue is a known debilitating issue for many cancer survivors, yet prevalence and severity of long-term fatigue in patients treated for OPC is unknown.
Method: As part of a mixed-methods study, fatigue in OPC patients ≥ 2 years post RT + / - chemotherapy was evaluated.
J Colloid Interface Sci
January 2025
State Key Laboratory of New Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, Key Laboratory of Analytical Science and Technology of Hebei Province, College of Chemistry and Materials Science, Hebei University 071002 Baoding, PR China. Electronic address:
In this study, a Co doped polyhedral carbon skeleton (Co CN) was prepared by nitrogen carbonization using ZIF-67 as a precursor. The Co CN features a rough surface with excellent electrical conductivity, and the Co atoms exhibit unique catalytic properties. Based on these characteristics, we used Co CN as a carrier to load Au nanoparticles (NPs) onto its surface through the linkage and reduction effects of polyoxometalates (POMs).
View Article and Find Full Text PDFJ Neurol
January 2025
Division of Child Neurology, Children's Hospital of Philadelphia, Departments of Neurology and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Background: The presented study identified the appropriate ocrelizumab dosing regimen for patients with pediatric-onset multiple sclerosis (POMS).
Methods: Patients with POMS aged 10-17 years were enrolled into cohort 1 (body weight [BW] < 40 kg, ocrelizumab 300 mg) and cohort 2 (BW ≥ 40 kg, ocrelizumab 600 mg) during a 24-week dose-exploration period (DEP), followed by an optional ocrelizumab (given every 24 weeks) extension period.
Primary Endpoints: pharmacokinetics, pharmacodynamics (CD19 B-cell count); secondary endpoint: safety; exploratory endpoints: MRI activity, protocol-defined relapses, Expanded Disability Status Scale (EDSS) score change.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!